Published by Coherent Market Insights
Posted on September 28, 2021
Burkholderia Infections Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Burkholderia Infections Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/153
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Novabiotics Ltd, iQur Ltd, Aridis Pharmaceuticals LLC, NanoBio Corporation, SUN pharma
Market Overview:
Burkholderia infections are caused by a group of viruses that are common in the animal kingdom. They include the herpes simplex virus (HSV), the Epstein-Barr virus (EBV), and the cytomegalovirus (CMD). These viruses often attack the skin, eyes, and respiratory systems, causing fever, skin rash, diarrhea, and other problems. The name ‘burkholderia’ comes from the word burk, an archaic word for cattle.
Key Market Drivers:
The increasing prevalence of lung disease around the globe is driving growth of the Burkholderia infections market. According to the World Health Organization, About 65 million people suffer from the chronic obstructive pulmonary disease (COPD), and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Thus growing cases of respiratory disease is fueling growth of the market.
Growing research and developments programs in the field is fostering growth of the market. For instance, in January 2020, The Cystic Fibrosis (CF) Foundation awarded nearly $700,000 contract to Calibr, the drug discovery, and development arm of Scripps Research, to support projects aiming to identify compounds that could treat infections caused by Burkholderia cepacia complex. The contract will provide funding for two years and is valued at $692,000
Covid-19 Impact Analysis
The COVID -19 has spread to almost every country around the world and World Health Organization has declared it a public health emergency. The global impacts of the coronavirus disease 2019 has a significant impact on the Burkholderia Infections market in 2020. The market was positively impacted as there was a rise in the cases of covid-19 patients with lung disease and weak immune systems.
Key Takeaways:
The Burkholderia infections market is expected to exhibit a CAGR of XX % over the forecast period, owing to the continuous launch of a new drug with high efficacy. For instance, in October 2018, Synspira, a company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, announced that it has been granted Orphan Designation by the United States Food and Drug Administration (FDA) for poly (acetyl, arginyl) glucosamine (PAAG15A), for the treatment of cystic fibrosis.
North America is expected to hold a dominant position in the global Burkholderia infections market and this is attributed to the high prevalence of lung disease in the region. The National Center for Health Statistics reports that the prevalence of physician ambulatory-care visits for respiratory diseases is highest in persons aged >85 years and is 57% and 85% lower in those aged 75 to 84 years and 65 to 74 years, respectively.
Buy This Premium Report Of Burkholderia Infections Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/153
In this study, the years considered to estimate the market size of Burkholderia Infections are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Burkholderia Infections Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Burkholderia Infections Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Burkholderia Infections Market Revenue , Export, and Import Status of Each Region appeared first on Gatorledger.
Burkholderia Infections Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Burkholderia Infections Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/153
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Novabiotics Ltd, iQur Ltd, Aridis Pharmaceuticals LLC, NanoBio Corporation, SUN pharma
Market Overview:
Burkholderia infections are caused by a group of viruses that are common in the animal kingdom. They include the herpes simplex virus (HSV), the Epstein-Barr virus (EBV), and the cytomegalovirus (CMD). These viruses often attack the skin, eyes, and respiratory systems, causing fever, skin rash, diarrhea, and other problems. The name ‘burkholderia’ comes from the word burk, an archaic word for cattle.
Key Market Drivers:
The increasing prevalence of lung disease around the globe is driving growth of the Burkholderia infections market. According to the World Health Organization, About 65 million people suffer from the chronic obstructive pulmonary disease (COPD), and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Thus growing cases of respiratory disease is fueling growth of the market.
Growing research and developments programs in the field is fostering growth of the market. For instance, in January 2020, The Cystic Fibrosis (CF) Foundation awarded nearly $700,000 contract to Calibr, the drug discovery, and development arm of Scripps Research, to support projects aiming to identify compounds that could treat infections caused by Burkholderia cepacia complex. The contract will provide funding for two years and is valued at $692,000
Covid-19 Impact Analysis
The COVID -19 has spread to almost every country around the world and World Health Organization has declared it a public health emergency. The global impacts of the coronavirus disease 2019 has a significant impact on the Burkholderia Infections market in 2020. The market was positively impacted as there was a rise in the cases of covid-19 patients with lung disease and weak immune systems.
Key Takeaways:
The Burkholderia infections market is expected to exhibit a CAGR of XX % over the forecast period, owing to the continuous launch of a new drug with high efficacy. For instance, in October 2018, Synspira, a company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, announced that it has been granted Orphan Designation by the United States Food and Drug Administration (FDA) for poly (acetyl, arginyl) glucosamine (PAAG15A), for the treatment of cystic fibrosis.
North America is expected to hold a dominant position in the global Burkholderia infections market and this is attributed to the high prevalence of lung disease in the region. The National Center for Health Statistics reports that the prevalence of physician ambulatory-care visits for respiratory diseases is highest in persons aged >85 years and is 57% and 85% lower in those aged 75 to 84 years and 65 to 74 years, respectively.
Buy This Premium Report Of Burkholderia Infections Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/153
In this study, the years considered to estimate the market size of Burkholderia Infections are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Burkholderia Infections Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Burkholderia Infections Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Burkholderia Infections Market Revenue , Export, and Import Status of Each Region appeared first on Gatorledger.
Explore more articles in the Research Reports category
